Reviewing the bioequivalence study of the antidiabetic drug Semaglutide of MSN Laboratories, the Subject Expert Committee ...

Sun Pharma's clinical trial failure impacts SPARC stock, highlighting the challenges in derma-oncology research.

Drug major Cipla has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...